Biomarin Pharmaceutical Inc (BMRN)
88.63
-1.45
(-1.61%)
USD |
NASDAQ |
Apr 19, 16:00
88.63
0.00 (0.00%)
After-Hours: 20:00
Biomarin Pharmaceutical Enterprise Value: 17.01B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 17.01B |
| April 17, 2024 | 17.08B |
| April 16, 2024 | 17.16B |
| April 15, 2024 | 17.28B |
| April 12, 2024 | 17.41B |
| April 11, 2024 | 17.27B |
| April 10, 2024 | 17.03B |
| April 09, 2024 | 16.80B |
| April 08, 2024 | 16.48B |
| April 05, 2024 | 16.42B |
| April 04, 2024 | 16.41B |
| April 03, 2024 | 16.39B |
| April 02, 2024 | 16.39B |
| April 01, 2024 | 16.45B |
| March 28, 2024 | 16.49B |
| March 27, 2024 | 16.73B |
| March 26, 2024 | 16.57B |
| March 25, 2024 | 16.34B |
| March 22, 2024 | 16.08B |
| March 21, 2024 | 15.88B |
| March 20, 2024 | 16.01B |
| March 19, 2024 | 16.10B |
| March 18, 2024 | 15.83B |
| March 15, 2024 | 15.84B |
| March 14, 2024 | 15.94B |
| Date | Value |
|---|---|
| March 13, 2024 | 16.01B |
| March 12, 2024 | 16.08B |
| March 11, 2024 | 16.24B |
| March 08, 2024 | 16.23B |
| March 07, 2024 | 16.22B |
| March 06, 2024 | 16.38B |
| March 05, 2024 | 16.24B |
| March 04, 2024 | 16.56B |
| March 01, 2024 | 16.45B |
| February 29, 2024 | 16.29B |
| February 28, 2024 | 16.69B |
| February 27, 2024 | 17.12B |
| February 26, 2024 | 17.01B |
| February 23, 2024 | 17.23B |
| February 22, 2024 | 16.99B |
| February 21, 2024 | 16.72B |
| February 20, 2024 | 16.74B |
| February 16, 2024 | 16.76B |
| February 15, 2024 | 16.67B |
| February 14, 2024 | 16.23B |
| February 13, 2024 | 16.26B |
| February 12, 2024 | 16.64B |
| February 09, 2024 | 16.70B |
| February 08, 2024 | 16.64B |
| February 07, 2024 | 16.92B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
11.67B
Minimum
Oct 02 2019
23.80B
Maximum
Jul 20 2020
15.95B
Average
15.64B
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 731.61B |
| Pfizer Inc | 201.80B |
| Regeneron Pharmaceuticals Inc | 89.21B |
| Vertex Pharmaceuticals Inc | 90.42B |
| Moderna Inc | 30.45B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.38M |
| Revenue (Quarterly) | 646.21M |
| Total Expenses (Quarterly) | 631.93M |
| EPS Diluted (Quarterly) | 0.11 |
| Gross Profit Margin (Quarterly) | 79.03% |
| Profit Margin (Quarterly) | 3.15% |
| Earnings Yield | 0.99% |
| Operating Earnings Yield | 0.93% |
| Normalized Earnings Yield | 0.9929 |